TG Therapeutics, Inc. recently shared promising data from three Phase 3 trials assessing the efficacy of BRIUMVI (ublituximab-xiiy) in treating patients with relapsing forms of multiple sclerosis (RMS). The findings were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum in West Palm Beach, Florida.
:This article aims to ly summarize the key facts and implications of the data presented by TG Therapeutics regarding the use of BRIUMVI in treating RMS.
Key Findings:The ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial collectively demonstrated the effectiveness of BRIUMVI in managing relapsing forms of multiple sclerosis. These trials involved a considerable number of patients and were conducted over a significant duration, enabling a comprehensive assessment of the drug’s safety and efficacy.
In the ULTIMATE I trial, patients receiving BRIUMVI experienced a statistically significant 38% lower annualized relapse rate (ARR) compared to those on placebo (p
Comments